Novartis AG CEO Vas Narasimhan says the revamp of the drugmaker's Sandoz business will be a multi-year journey during which the biggest driver will be the biosimilars market. He also discusses Covid-19 vaccines in an interview on Bloomberg Television after Novartis's first-quarter profit fell as the pandemic continued to depress demand for some medicines. (Source: Bloomberg)